Jyrki Mattila, MD, PhD
Jyrki
Mattila is the Chairman of the Board of Aranda Pharma Ltd. Jyrki
has over 30 years of experience in managerial positions in the pharmaceutical
industry of which the past 16 years he has spent in the US. Currently he holds
a position of Executive Vice President, Business Development at Recro Pharma.
In the past he has served as Chief Business Officer at Lipocine and at iCeutica
Inc. and as President and Chief Executive Officer at LZ Therapeutics, Inc. At
Auxilium Pharmaceuticals Inc, Jyrki served as Executive Vice President,
Business Development, Product Development and Technical Operations and
contributed to Auxilium’s growth from a private start-up to a publicly-traded
specialty pharmaceutical company. Prior moving to US, Jyrki held positions of
increasing responsibility at Orion Corporation in business development, R&D
and executive general management. Jyrki served as a Post-Doctoral Research
Fellow at the University of Kansas Medical Center and holds a M.B.A. from the
Helsinki School of Economics, a Ph.D. from the Department of Pharmacology at
the University of Helsinki and a M.D. from the University of Helsinki Medical
School.
Aki Prihti, MSc (Econ, BA)
Aki Prihti is a Non-Executive Director and Board member of Aranda Pharma Ltd. Aki has close to 20 years of experience in setting up, developing, and funding life science growth companies. Currently Aki serves as CEO of Aplagon Oy, a Finnish drug development company focused on vascular intervention related complications, and as CFO and Board member of Medtentia International Ltd Oy, a Finnish medical device company focused on catheter based mitral valve repair. Aki is also one of the founders of Inveni Capital, a life sciences focused venture capital fund, and a board member of Herantis Pharma Oyj. Aki received his MSc in Economy and Business Administration from Helsinki School of Economics and Business Administration, Finland.